Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 5/20 | 0.70 |
| ▸ | TRPC3 | Q13507 | 3/20 | 0.70 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.70 |
| ▸ | SLC9A3 | P48764 | 15/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410065 | 0.94 | TRPC6 (0.73) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2408820 | 0.94 | TRPC6 (0.73) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL12363380 | 0.94 | TRPC6 (0.73) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2414847 | 0.86 | TRPC6 (0.89) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL12363384 | 0.86 | TRPC6 (0.89) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2410193 | 0.86 | TRPC6 (0.89) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2410177 | 0.85 | TRPC6 (0.67) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL12363213 | 0.85 | TRPC6 (0.53) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2413044 | 0.84 | TRPC6 (0.59) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2413989 | 0.83 | TRPC6 (0.58) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| US-9550788-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2017-01-24 | — | — | US | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI (FR) | 2014-11-27 | — | — | US | disclosed |
| US-8822449-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-8822449-B2 | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | SANOFI-AVENTIS (FR) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201590-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, PKD1 | TRPC6 2782/4885TRPC3 1207/4885TRPC7 2539/4885 |
| US-20140349986-A1 | SUBSTITUTED AMINOINDANES AND ANALOGS THEREOF, AND THE PHARMACEUTICAL USE THEREOF | CFTR, AADAT, FANCI | TRPC6 3028/4885TRPC3 1262/4885TRPC7 2774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.